ASCO Lung Cancer 2022 – Jessica Donington

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Jessica Donington highlights the most promising agents currently investigated in the neoadjuvant setting in patients with resectable NSCLC, how the “intensity” of neoadjuvant treatment affects the outcomes and discusses if neoadjuvant chemo-immunotherapy is the new standard of care. She outlines which variables related to surgery itself are determinants of the success of curative surgery and which biomarkers are on the rise to guide therapy.

Here is the full ASCO 2022 Lung Cancer report.